- XORTX Therapeutics is preparing a Clinical Trial Application (CTA) to Health Canada for XRx-026, its gout program evaluating Xorlo, a proprietary formulation of oxypurinol, a xanthine oxidase inhibitor.
- The planned two-part XRX-OXY-102 study will begin with a Canadian clinical trial component, building on previously reported positive results and further characterizing Xorlo’s commercial tablet formulation.
- The Canadian study is expected to accelerate clinical data generation supporting XORTX’s planned U.S. FDA New Drug Application (NDA), while advancing a parallel regulatory strategy in Canada.
- XORTX reports increased inquiries from potential commercialization partners across several jurisdictions, but no agreements have been signed. The program targets a growing gout burden, with global cases projected to rise 70% over the next 25 years.
Takeaways:
XORTX’s planned Canadian CTA could strengthen XORLO’s regulatory pathway while generating clinical evidence to support a future U.S. NDA. The proprietary oxypurinol formulation may offer a route to differentiate in gout treatment, but commercial prospects will depend on clinical validation, regulatory progress, and converting partner interest into agreements.
Source: Globenewswire
